Maravai LifeSciences (MRVI) Expected to Announce Earnings on Tuesday

Maravai LifeSciences (NASDAQ:MRVI) is projected to release its earnings data after the market closes on Tuesday, February 25th. Analysts expect Maravai LifeSciences to post earnings of ($0.03) per share and revenue of $57.79 million for the quarter. Persons that wish to register for the company’s earnings conference call can do so using this link.

Maravai LifeSciences Stock Performance

Shares of MRVI stock opened at $4.11 on Friday. The company has a 50 day moving average price of $5.06 and a 200-day moving average price of $6.66. Maravai LifeSciences has a 52 week low of $3.93 and a 52 week high of $11.56. The firm has a market capitalization of $1.04 billion, a PE ratio of -2.51 and a beta of -0.08. The company has a quick ratio of 9.94, a current ratio of 10.74 and a debt-to-equity ratio of 0.89.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the stock. Guggenheim assumed coverage on shares of Maravai LifeSciences in a report on Thursday, December 19th. They issued a “neutral” rating on the stock. William Blair reiterated a “market perform” rating on shares of Maravai LifeSciences in a research report on Friday, November 8th. Robert W. Baird lowered their price objective on shares of Maravai LifeSciences from $10.00 to $9.00 and set an “outperform” rating for the company in a research note on Friday, November 8th. Royal Bank of Canada decreased their price target on shares of Maravai LifeSciences from $17.00 to $13.00 and set an “outperform” rating for the company in a research report on Friday, November 8th. Finally, The Goldman Sachs Group lowered shares of Maravai LifeSciences from a “neutral” rating to a “sell” rating and decreased their price objective for the company from $7.00 to $4.25 in a research report on Thursday, December 5th. One analyst has rated the stock with a sell rating, five have issued a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $10.28.

Insider Buying and Selling

In related news, General Counsel Kurt Oreshack sold 25,000 shares of the stock in a transaction on Friday, January 31st. The stock was sold at an average price of $5.03, for a total transaction of $125,750.00. Following the sale, the general counsel now owns 167,618 shares of the company’s stock, valued at $843,118.54. This trade represents a 12.98 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.63% of the stock is currently owned by corporate insiders.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.